Hepatic lesion – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 11:28:39 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hepatic lesion – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Safety and Effectiveness of Intravenous Sonazoid for Contrast-Enhanced Liver Ultrasound in Children with Focal Liver Lesions https://clinicaltrials.eu/trial/safety-and-effectiveness-of-intravenous-sonazoid-for-contrast-enhanced-liver-ultrasound-in-children-with-focal-liver-lesions/ Wed, 29 Apr 2026 15:06:06 +0000 https://clinicaltrials.eu/trial/safety-and-effectiveness-of-intravenous-sonazoid-for-contrast-enhanced-liver-ultrasound-in-children-with-focal-liver-lesions/ This study focuses on evaluating Sonazoid™ (perflubutane microbubbles) for imaging focal liver lesions in children and adolescents under 18 years of age. Focal liver lesions are abnormal areas or growths in the liver tissue that can be either benign (non-cancerous) or malignant (cancerous). The purpose of the study is to assess how accurately Sonazoid™ can help doctors distinguish between benign and malignant liver lesions when used during contrast-enhanced ultrasound imaging.

Contrast-enhanced ultrasound is a technique where special contrast agents like Sonazoid™ are injected into the bloodstream to improve the visibility of internal organs and blood vessels during an ultrasound examination. During the study, participants will receive Sonazoid™ intravenously (through a vein) while undergoing ultrasound imaging of their liver. The images will be taken during different phases including the vascular phase (when the contrast agent is flowing through blood vessels) and the Kupffer phase (when the contrast agent is taken up by special cells in the liver).

The study will compare the images obtained with Sonazoid™ to those from regular ultrasound without contrast, as well as to the participant’s baseline diagnosis established through other imaging methods like contrast-enhanced computed tomography (CECT) or contrast-enhanced magnetic resonance imaging (CEMRI). Participants will be monitored for safety for 72 hours after receiving Sonazoid™.

]]>